| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)- Basic information |
| Product Name: | 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)- | | Synonyms: | 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)-;(S)-1-((R)-2-(4-(2-chloro-4-fluorophenyl)-2-oxo-2H-chromen-7-yloxy)propanoyl)piperidine-3-carboxylic acid;Inhibitor,inhibit,POLRMT,oxidative,IMT-1B,LDC-203974,human,LDC 203974,anti-tumour,mtDNA,phosphorylation,IMT1B,OXPHOS,RNA,mitochondrial,DNA,polymerase;(3S)-1-[(2R)-2-[[4-(2-Chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-3-piperidinecarboxylic acid;IMT1B (LDC203974);IMT1B, 10 mM in DMSO | | CAS: | 2304621-06-3 | | MF: | C24H21ClFNO6 | | MW: | 473.88 | | EINECS: | | | Product Categories: | | | Mol File: | 2304621-06-3.mol | ![3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)- Structure](CAS/20200611/GIF/2304621-06-3.gif) |
| | 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)- Chemical Properties |
| Boiling point | 705.7±60.0 °C(Predicted) | | density | 1.426±0.06 g/cm3(Predicted) | | pka | 4.33±0.20(Predicted) | | form | Solid | | color | White to off-white | | InChIKey | PFEKWBKJUBCXDT-KGLIPLIRSA-N | | SMILES | N1(C(=O)[C@H](OC2=CC=C3C(=C2)OC(=O)C=C3C2=CC=C(F)C=C2Cl)C)CCC[C@H](C(O)=O)C1 |
| | 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)- Usage And Synthesis |
| Uses | IMT1B (LDC203974) is an orally active, noncompetitive and specific allosteric inhibitor of mitochondrial RNA polymerase (POLRMT) and inhibits mitochondrial DNA (mtDNA) expression. IMT1B has anti-tumour effects[1]. | | in vivo | IMT1B (100 mg/kg; p.o.; daily; for four weeks) significantly reduces tumour size in mice containing xenografts[1].
IMT1B reduces mtDNA transcript levels and respiratory-chain subunit levels in tumours[1].
IMT1B exhibits good oral bioavailability (mice 101 %) and Cmax (mice 5149 ng/mL) following oral administration (mice 10 mg/kg)[1].
IMT1B exhibits elimination half-life (mice 1.88 h) due to plasma clearance (mice 0.44 L/h/kg) following intravenous administration (mice 1 mg/kg)[1].
| Animal Model: | 7-9 weeks female BALB/c nude mice, with A2780 cells xenograft[1] | | Dosage: | 100 mg/kg | | Administration: | Oral administration, daily, for four weeks | | Result: | Led to a clear reduction of tumour volume. |
| Animal Model: | Mice[1] | | Dosage: | 1 mg/kg for i.v.; 10 mg/kg for oral (Pharmacokinetic Analysis) | | Administration: | Intravenous administration and oral administration | | Result: | Oral bioavailability (101%), Cmax (5149 ng/mL), T1/2 (1.88 h). |
| | References | [1] Nina A Bonekamp, et al. Small-molecule inhibitors of human mitochondrial DNA transcription. Nature. 2020 Dec;588(7839):712-716. DOI:10.1038/s41586-020-03048-z |
| | 3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)- Preparation Products And Raw materials |
|